BLA 019959 · Novo Nordisk INC
Novolin N
Insulin Susp Isophane Recombinant Human · Injection · Insulin
Last checked: Nov 20, 2026Latest source record: Nov 23, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1991
Jul 1, 1991
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
0 Phase 3, 0 recruiting
FAERS reports
6,504
4,443 serious, 593 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 23, 2022.
NOVOLIN N is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. NOVOLIN N is an intermediate-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. ( 1 )
Mechanism: The primary activity of insulin, including NOVOLIN N is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 1, 1991 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- NOVOLIN N · INSULIN SUSP ISOPHANE RECOMBINANT HUMAN 100 UNITS/ML · INJECTABLE, INJECTION · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Susp Isophane Recombinant Human" as an intervention, any sponsor and status, largest first.
Biocon LimitedIndustry
NCT04022304 · 90 participants · Start Jun 15, 2019 · Primary completion Dec 21, 2019
Drug: Biocon Insulin N; Humulin® N · For: Healthy Volunteer
Sites: Neuss, Germany
Biocon LimitedIndustry
NCT04022291 · 78 participants · Start Jun 15, 2019 · Primary completion Jan 20, 2020
Drug: Humulin ®70/30; Biocon Insulin 70/30 · For: Healthy Volunteer
Sites: Mainz, Germany; Neuss, Germany
WockhardtIndustry
NCT01358435 · 53 participants · Start Jan 2011 · Primary completion May 2011
Drug: 30% Regular Insulin Human Neutral and 70%Isophane Insulin; Novolin 70/30 · For: Diabetes Mellitus
Sites: Chula Vista, California
GeropharmIndustry
NCT04501250 · 52 participants · Start Oct 23, 2017 · Primary completion Jan 1, 2018
Drug: Rinsulin NPH; Humulin NPH · For: Pharmacokinetics; Bioequivalence
Sites: Yaroslavl, Russia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased1,003
- blood glucose decreased365
- drug ineffective362
- nausea332
- dyspnoea281
- diarrhoea274
- dizziness234
- fatigue231
- death227
- hypoglycaemia225
- fall213
- malaise208
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 91 |
| 2005 | 150 |
| 2006 | 232 |
| 2007 | 144 |
| 2008 | 191 |
| 2009 | 246 |
| 2010 | 181 |
| 2011 | 144 |
| 2012 | 207 |
| 2013 | 242 |
| 2014 | 330 |
| 2015 | 769 |
| 2016 | 537 |
| 2017 | 568 |
| 2018 | 609 |
| 2019 | 569 |
| 2020 | 286 |
| 2021 | 246 |
| 2022 | 179 |
| 2023 | 138 |
| 2024 | 166 |
| 2025 | 193 |
| 2026 | 86 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Novolin N (Insulin NPh Human Isophane)
2024 spending
$14.0M
Beneficiaries
25,782
98,923 claims
Per beneficiary
$543
$4.44 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $70,350,615 |
| 2021 | $63,435,398 |
| 2022 | $59,244,051 |
| 2023 | $53,437,662 |
| 2024 | $13,990,145 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Novo Nordisk
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.